Enterprise Value
10.39M
Cash
33.98M
Avg Qtr Burn
-13.47M
Short % of Float
0.67%
Insider Ownership
25.79%
Institutional Own.
34.80%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XTX202 (combo therapy). Details Renal cell carcinoma, Melanoma | Phase 2 Update | |
XTX101 + atezolizumab Details Cancer, Colorectal cancer | Phase 2 Initiation | |
XTX301 Details Solid tumor/s | Phase 1 Data readout |